VM BioPharma receives South Korea MFDS approval for Phase II trial of VM202 to treat IHD

South Korean-based ViroMed ’s US biopharmaceutical division VM BioPharma has secured Investigational New Drug (IND) approval from the Ministry of Food and Drug Safety in Korea (MFDS) to conduct the Phase II clinical trial of VM202 for ischemic heart d…
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news